Immunomodulation in allogeneic marrow transplantation: Use of intravenous immune globulin to suppress acute graft-versus-host disease

Clinical and Experimental Immunology, Supplement

Volumn 104, Issue SUPPL. 1, 1996, Pages 43-48

  Sullivan, K M ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Bone marrow transplantation; CMV; GVHD; IVIG

Indexed keywords

IMMUNOGLOBULIN;

BACTERIAL INFECTION; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL;

ACUTE DISEASE; ADULT; BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0029914442     PISSN: 09642536     EISSN: None     Source Type: Journal    
DOI: 10.1111/cei.1996.104.s1.43     Document Type: Article

References (68)

1. Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation. N Engl J Med 1975; 292:832-43, 895-902.
2. Storb R, Etzioni R, Anasetti C et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplantation in patients with aplastic anemia. Blood 1994; 84:941-9.
3. Clift RA, Appelbaum FR, Thomas ED. Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993; 82:1954-6.
4. Beatty PG, Clift RA, Mickelson EM et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313:765-71.
5. Beatty PG, Hansen JA, Longton GM et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991; 51:443-7.
6. Sullivan KM, Deeg HJ, Sanders J et al. Hyperacute GVHD in patients not given immunosuppression after allogeneic marrow transplantation. Blood 1986; 67:1172-5.
7. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314:729-35.
8. Nash RA, Etzioni R, Storb R, et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft versus host disease after marrow transplantation from HLA-matched siblings: a single-center study. Blood 1995; 85: 3746-53.
9. Chao NJ, Schmidt GM, Niland JC et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329:1225-30.
10. Ferrara JLM, Deeg HF. Graft-versus-host disease. N Engl J Med 1991; 324:667-74.
11. Sullivan KM. Graft-versus-host disease. In: Forman SJ, Blume KG, Thomas ED, eds. Bone Marrow Transplantation. Boston: Blackwell Scientific Publications, 1994:339-62.
12. Sullivan KM, Shulman HM, Storb R et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57:267-76.
13. Vogelsang GB, Farmer ER, Hess AD et al. Thalidomide for the treatment of chronic graft versus host disease. N Engl J Med 1992; 326:1055-8.
14. Sullivan KM, Agura E, Anasetti C et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28:250-9.
15. Billingham RE. The biology of graft-versus-host reactions. In: The Harvey Lectures. New York: Academic Press, 1966;62:21-78.
16. Tsoi M. Immunological mechanisms of graft-versus-host disease in man. Transplantation 1982; 33:459-64.
17. Korngold R, Sprent J. T cell subsets and graft-versus-host disease. Transplantation 1987; 44:335-9.
18. Piguet P-F, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/ cachectin is an effector of skin and gut lesions of the acute phase of graft-vs-host disease. J Exp Med 1987; 166:1280-9.
19. Cohen J. Cytokines as mediators of graft-versus-host disease. Bone Marrow Transplant 1988; 3:193-7.
20. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus host disease. Blood 1992; 80:2964-8.
21. Rowbottom AW, Riches PG, Downie C, Hobbs JR. Monitoring cytokine production in peripheral blood during acute graft-versus-host disease following allogeneic bone marrow transplantation. Bone Marrow Transplant 1993; 12:635-41.
22. Abhyankar S, Gilliland DG, Ferrara JLM. Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens. Transplantation 1993; 56:1518-23.
23. van Bekkum DW, Knaan S. Role of bacterial microflora in development of intestinal lesions from graft-versus-host reaction. J Natl Cancer Inst 1977; 58:787-90.
24. Storb R, Prentice RL, Buckner CD et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings: beneficial effect of a protective environment. N Engl J Med 1983; 308:302-7.
25. Parkman R. Clonal analysis of murine graft-vs-host disease. J Immunol 1986; 136:3543-8.
26. Martin PJ, Hansen JA, Buckner CD et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 1985; 66:664-72.
27. Marmont AM, Horowitz MM, Gale RP et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-30.
28. + cells for prevention of graft-versus-host disease after bone marrow transplantation. Transplantation 1994; 57:82-7.
29. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann Intern Med 1988; 108:806-14.
30. Sullivan, KM, Weiden PL, Storb R et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA- identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73:1720-8.
31. Imbach P, Barandun S, d'Apuzzo V et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; i:1228-31.
32. Newburger JW, Takahashi M, Burns JC et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315:341-7.
33. Van der Meche FGA, Schmitz PIM and the Dutch Guillain-Barré Study Group: A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré Syndrome. N Engl J Med 1992; 326:1123-9.
34. Dalakas MC, Illa I, Dambrosia JM et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329:1993-2000.
35. Ronda N, Hurez V, Kazatchine MD. Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases. Vox Sang 1993; 64:65-72.
36. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326:107-16.
37. Kawada K, Terasaki PI. Evidence for immunosuppression by high-dose gammaglobulin. Exp Hematol 1987; 15:133-6.
38. Leung DY, Burns JC, Newburger JW, Geha RS. Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest 1987; 79:468-72.
39. Klaesson S, Ringden O, Markling L et al. Immune modulatory effect of immunoglobulins on cell-mediated immune responses in vitro. Scand J Immunol 1993; 38:477-84.
40. Delfraissy JF, Tchernia G, Laurian Y et al. Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. Br J Haematol 1985; 60: 315-22.
41. White WB, Desbonnet CR, Ballow M. Immunoregulatory effects of intravenous immune serum globulin therapy in common variable hypogammaglobulinemia. Am J Med 1987; 83:431-6.
42. Stohl W. Cellular mechanisms in the in vitro inhibition of pokeweed mitogen-induced B cell differentiation by immunoglobulin for intravenous use. J Immunol 1986; 136:4407-13.
43. Hashimoto F, Sakiyama Y, Matsumoto S. The suppressive effect of gammaglobulin preparations on in vitro pokeweed mitogen-induced immunoglobulin production. Clin Exp Immunol 1986; 65:409-15.
44. Kimberley RP, Salmon JE, Bussel JB et al. Modulation of mononuclear phagocyte function by intravenous gammaglobulin. J Immunol 1984; 132:745-50.
45. Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger VE. Antiidiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; ii:765-8.
46. Dietrich G, Kazatchkine MD. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human antithyroglobulin autoantibodies. J Clin Invest 1990; 85:620-5.
47. Cohen J, Moore RH, Al Hashimi S et al. Antibody titres to a rough-mutant strain of Escherichia coli in patients undergoing allogeneic bone marrow transplantation: evidence of a protective effect against graft-versus-host disease. Lancet 1987; i:8-11.
48. Aukrust P, Froland SS, Liabakk N-B et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84:2136-43.
49. Abe Y, Horiuchi A, Miyake M, Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994; 139:5-20.
50. Winston DJ, Pollard RB, Ho WG et al. Cytomegalovirus immune plasma in bone marrow transplant recipients. Ann Intern Med 1982; 97:11-18.
51. Meyers JD, Leszczynski J, Zaia JA et al. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med 1983; 98:442-6.
52. Bowden RA, Sayers M, Flournoy N et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986; 314:1006-10.
53. Winston DJ, Ho WG, Lin C-H et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 1987; 106:12-8.
54. Ringden O, Pihlstedt P, Volin L et al. Failure to prevent cytomegalovirus infection by cytomegalovirus hyperimmune plasma: a randomized trial by the Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant 1987; 2:299-305.
55. Sullivan KM. Immunoglobulin therapy in bone marrow transplantation. Am J Med 1987; 83(Suppl. 4A):34-45.
56. Bass EB, Powe NR, Goodman SN et al. Efficacy of immune globulin in preventing complications of bone marrow transplantation: A meta-analysis. Bone Marrow Transplant 1993; 12:273-82.
57. Messori A, Rampazzo R, Scroccaro G, Martini N. Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation - A meta-analysis. Bone Marrow Transplant 1994; 13:163-7.
58. Schmidt GM, Morak DA, Niland JC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic marrow transplants. N Engl J Med 1991; 324:1005-11.
59. Goodrich JM, Mori M, Cleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325:1601-7.
60. Petersen FB, Bowden RA, Thornquist M et al. The effect of prophylactic intravenous immune globulin on the incidence of septicemia in marrow transplant recipients. Bone Marrow Transplant 1987; 2:141-8.
61. Sullivan KM, Kopecky KJ, Jocom J et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990; 323:705-12.
62. Sullivan KM, Kopecky KJ, Buckner CD, Storb R. Intravenous IgG to prevent graft-versus-host disease after bone marrow transplantation (Letter). N Engl J Med 1991; 324:631-3.
63. Graham-Pole J, Camitta B, Casper J et al. Intravenous immunoglobulin may lessen all forms of infection in patients receiving allogeneic bone marrow transplantation for acute Iymphoblastic leukemia: a pediatric oncology group study. Bone Marrow Transplant 1988; 3:559-66.
64. Winston DJ, Ho WG, Bartoni K, Champlin RE. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12:283-8.
65. Emanuel D, Taylor J, Brochstein J et al. The use of intravenous immune globulin as prophylaxis for the infectious complications of allogeneic marrow transplantation. Blood 1992; 80(Suppl. 1):271a (Abstract).
66. Cottler-Fox M, Lynch M, Pickle LW et al. Some but not all benefits of intravenous immunoglobulin therapy after marrow transplantation appear to correlate with IgG trough levels. Bone Marrow Transplant 1991; 8:27-33.
67. Sullivan KM, Storek J, Kopecky KJ et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-versus-host disease following marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant 1995, in press.
68. Sullivan KM, Offner F, Herold M et al. Relationship of serum cytokines (TNF-α, IL-1β, IFN-γ) and inflammation markers (neopterin, β2-microglobulin, C-reactive protein) to transplant-related complications and immunoglobulin prophylaxis following allogeneic marrow transplantation. Blood 1994; 84:398 (Abstract).